Pharmacology, Efficacy and Safety of a Triple-Secured Fibrinogen Concentrate in Children Less than or Equal to 12 Years with Afibrinogenaemia

Khayat C. D., El Khorassani M., Aytac Ş. S., Harroche A., Dahmane A., Pujol S., ...Daha Fazla

THROMBOSIS AND HAEMOSTASIS, cilt.120, sa.6, ss.957-967, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 120 Sayı: 6
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1055/s-0040-1710015
  • Dergi Adı: THROMBOSIS AND HAEMOSTASIS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, PASCAL, BIOSIS, CAB Abstracts, Chemical Abstracts Core, EMBASE, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.957-967
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Objective To date, the use of a fibrinogen concentrate (FC) administered in children with inherited fibrinogen deficiency is poorly documented. Treatment modalities may differ from those of adults. The aim of this study was to investigate the pharmacokinetics (PK), efficacy (bleeding/surgery) and safety of a triple-secured FC (FibCLOT, LFB, France) in young patients aged of 12 years or less.